Literature DB >> 19458006

Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases.

Jörg Zielonka1, Ignacio G Bravo, Daniela Marino, Elea Conrad, Mario Perković, Marion Battenberg, Klaus Cichutek, Carsten Münk.   

Abstract

The mammalian APOBEC3 (A3) proteins comprise a multigene family of cytidine deaminases that act as potent inhibitors of retroviruses and retrotransposons. The A3 locus on the chromosome 28 of the horse genome contains multiple A3 genes: two copies of A3Z1, five copies of A3Z2, and a single copy of A3Z3, indicating a complex evolution of multiple gene duplications. We have cloned and analyzed for expression the different equine A3 genes and examined as well the subcellular distribution of the corresponding proteins. Additionally, we have tested the functional antiretroviral activity of the equine and of several of the human and nonprimate A3 proteins against the Equine infectious anemia virus (EIAV), the Simian immunodeficiency virus (SIV), and the Adeno-associated virus type 2 (AAV-2). Hematopoietic cells of horses express at least five different A3s: A3Z1b, A3Z2a-Z2b, A3Z2c-Z2d, A3Z2e, and A3Z3, whereas circulating macrophages, the natural target of EIAV, express only part of the A3 repertoire. The five A3Z2 tandem copies arose after three consecutive, recent duplication events in the horse lineage, after the split between Equidae and Carnivora. The duplicated genes show different antiviral activities against different viruses: equine A3Z3 and A3Z2c-Z2d are potent inhibitors of EIAV while equine A3Z1b, A3Z2a-Z2b, A3Z2e showed only weak anti-EIAV activity. Equine A3Z1b and A3Z3 restricted AAV and all equine A3s, except A3Z1b, inhibited SIV. We hypothesize that the horse A3 genes are undergoing a process of subfunctionalization in their respective viral specificities, which might provide the evolutionary advantage for keeping five copies of the original gene.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19458006      PMCID: PMC2708611          DOI: 10.1128/JVI.00015-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  98 in total

1.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

2.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

3.  MUSCLE: multiple sequence alignment with high accuracy and high throughput.

Authors:  Robert C Edgar
Journal:  Nucleic Acids Res       Date:  2004-03-19       Impact factor: 16.971

4.  APOBEC3G targets specific virus species.

Authors:  Masayuki Kobayashi; Akifumi Takaori-Kondo; Keisuke Shindo; Aierken Abudu; Keiko Fukunaga; Takashi Uchiyama
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

5.  Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha.

Authors:  Theodora Hatziioannou; David Perez-Caballero; Annie Yang; Simone Cowan; Paul D Bieniasz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

6.  A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).

Authors:  Bärbel Schröfelbauer; Darlene Chen; Nathaniel R Landau
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

7.  Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.

Authors:  Yong-Hui Zheng; Dan Irwin; Takeshi Kurosu; Kenzo Tokunaga; Tetsutaro Sata; B Matija Peterlin
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 8.  Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us?

Authors:  Caroline Leroux; Jean-Luc Cadoré; Ronald C Montelaro
Journal:  Vet Res       Date:  2004 Jul-Aug       Impact factor: 3.683

9.  HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.

Authors:  Mariana Marin; Kristine M Rose; Susan L Kozak; David Kabat
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

10.  Cytidine deamination of retroviral DNA by diverse APOBEC proteins.

Authors:  Kate N Bishop; Rebecca K Holmes; Ann M Sheehy; Nicholas O Davidson; Soo-Jin Cho; Michael H Malim
Journal:  Curr Biol       Date:  2004-08-10       Impact factor: 10.834

View more
  25 in total

1.  The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.

Authors:  Marcel Ooms; Susan Majdak; Christopher W Seibert; Ariana Harari; Viviana Simon
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

Review 2.  Functions and regulation of the APOBEC family of proteins.

Authors:  Harold C Smith; Ryan P Bennett; Ayse Kizilyer; William M McDougall; Kimberly M Prohaska
Journal:  Semin Cell Dev Biol       Date:  2011-10-06       Impact factor: 7.727

3.  In Vivo Examination of Mouse APOBEC3- and Human APOBEC3A- and APOBEC3G-Mediated Restriction of Parvovirus and Herpesvirus Infection in Mouse Models.

Authors:  Yuki Nakaya; Spyridon Stavrou; Kristin Blouch; Peter Tattersall; Susan R Ross
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

4.  Polymorphism in human APOBEC3H affects a phenotype dominant for subcellular localization and antiviral activity.

Authors:  Melody M H Li; Michael Emerman
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

5.  Vif of feline immunodeficiency virus from domestic cats protects against APOBEC3 restriction factors from many felids.

Authors:  Jörg Zielonka; Daniela Marino; Henning Hofmann; Naoya Yuhki; Martin Löchelt; Carsten Münk
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

6.  Genomic analysis of an effective lentiviral vaccine-attenuated equine infectious anemia virus vaccine EIAV FDDV13.

Authors:  Xu Qi; Xuefeng Wang; Shuai Wang; Yuezhi Lin; Chenggang Jiang; Jian Ma; Liping Zhao; Xiaoling Lv; Rongxian Shen; Fenglong Wang; Xiangang Kong; Zhiqiang Su; Jianhua Zhou
Journal:  Virus Genes       Date:  2010-06-05       Impact factor: 2.332

7.  Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.

Authors:  John S Albin; Guylaine Haché; Judd F Hultquist; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

8.  Restriction of porcine endogenous retrovirus by porcine APOBEC3 cytidine deaminases.

Authors:  Eva Dörrschuck; Nicole Fischer; Ignacio G Bravo; Kay-Martin Hanschmann; Heidi Kuiper; Andreas Spötter; Ronny Möller; Klaus Cichutek; Carsten Münk; Ralf R Tönjes
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

9.  Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex.

Authors:  Spyridon Stavrou; Takayuki Nitta; Swathi Kotla; Dat Ha; Kunio Nagashima; Alan R Rein; Hung Fan; Susan R Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-13       Impact factor: 11.205

10.  Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein.

Authors:  Xin Yin; Zhe Hu; Qinyong Gu; Xingliang Wu; Yong-Hui Zheng; Ping Wei; Xiaojun Wang
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.